Healthy Aging Through Lifelong Vaccination: A Tale of Two Countries

• Westra TA , ParoutyM, BrouwerWBet al. On discounting of health gains from human papillomavirus vaccination: effects of different approaches. Value Health 15(3), 562–567(2012).
   PubMed Web of Science ®Google Scholar
• Postma MJ , WestraTA, QuiliciS, LargeronN. Economic evaluation of vaccines: specificities and future challenges illustrated by recent European examples. Expert Rev. Vaccines12(5), 555–565(2013).
   PubMed Web of Science ®Google Scholar
• Rozenbaum MH , MangenMJ, GiaquintoC, WilschutJC, HakE, Postma MJ; Consensus Group on Dutch Rotavirus Vaccination (CoRoVa-Group). Cost–effectiveness of rotavirus vaccination in The Netherlands; the results of a consensus model. BMC Public Health11, 462 (2011).
   PubMedGoogle Scholar
• Tu HA , WoerdenbagHJ, KaneS, RozenbaumMH, LiSC, PostmaMJ. Economic evaluations of rotavirus immunization for developing countries: a review of the literature. Expert Rev. Vaccines10(7), 1037–1051(2011).
   PubMed Web of Science ®Google Scholar
• Bilcke J , VanDP, BeutelsP. Cost–effectiveness of rotavirus vaccination: exploring caregiver(s) and ‘no medical care’ disease impact in Belgium. Med. Decis. Making29(1), 33–50(2009).
   PubMed Web of Science ®Google Scholar
• Friesema IH , de Boer RF, Duizer E et al. Etiology of acute gastroenteritis in children requiring hospitalization in The Netherlands. Eur. J. Clin. Microbiol. Infect. Dis.31(4), 405–415(2012).
   PubMed Web of Science ®Google Scholar
• Tu HA , RozenbaumMH, de Boer PT, Noort AC, Postma MJ. An update of ‘cost–effectiveness of rotavirus vaccination in The Netherlands: the results of a consensus rotavirus vaccine model’. BMC Infect. Dis.13, 54 (2013).
   PubMed Web of Science ®Google Scholar
• Glass RI . Unexpected benefits of rotavirus vaccination in the United States. J. Infect. Dis.204(7), 975–977(2011).
   PubMed Web of Science ®Google Scholar
• Pertussis vaccines: WHO position paper. Wkly Epidemiol. Rec.85(40), 385–400(2010).
   PubMedGoogle Scholar
• Celentano LP , MassariM, ParamattiD, SalmasoS, TozziAE. Resurgence of pertussis in Europe. Pediatr. Infect. Dis. J.24(9), 761–765(2005).
   PubMed Web of Science ®Google Scholar
• de Greeff SC , MooiFR, SchellekensJF, de Melker HE. Impact of acellular pertussis preschool booster vaccination on disease burden of pertussis in The Netherlands. Pediatr. Infect. Dis. J.27(3), 218–223(2008).
   PubMed Web of Science ®Google Scholar
• Quinn HE , McIntyrePB. Pertussis epidemiology in Australia over the decade 1995–2005 – trends by region and age group. Commun. Dis. Intell.31(2), fpage>205–215(2007).
   Google Scholar
• de Vries R , KretzschmarM, SchellekensJFet al. Cost–effectiveness of adolescent pertussis vaccination for The Netherlands: using an individual-based dynamic model. PLoS ONE 5(10), e13392 (2010).
   PubMed Web of Science ®Google Scholar
• Rozenbaum MH , de Vries R, Le HH, Postma MJ. Modelling the impact of extended vaccination strategies on the epidemiology of pertussis. Epidemiol. Infect.140(8), 1503–1514(2011).
   PubMed Web of Science ®Google Scholar
• Rozenbaum MH , de Vries CE, Postma MJ. Cost–effectiveness of pertussis booster vaccination in The Netherlands. Vaccine30(50), 7327–7331(2012).
   PubMed Web of Science ®Google Scholar
• Mossong J , HensN, JitMet al. Social contacts and mixing patterns relevant to the spread of infectious diseases. PLoS Med. 5(3), e74 (2008).
   PubMed Web of Science ®Google Scholar
• Wallinga J , TeunisP, KretzschmarM. Using data on social contacts to estimate age-specific transmission parameters for respiratory-spread infectious agents. Am. J. Epidemiol.164(10), 936–944(2006).
   PubMed Web of Science ®Google Scholar
• O‘Mahony JF , de Kok IM, van RJ, Habbema JD, Brouwer W, van BM. Practical implications of differential discounting in cost–effectiveness analyses with varying numbers of cohorts. Value Health14(4), 438–442(2011).
   PubMed Web of Science ®Google Scholar
• Rozenbaum MH , PostmaMJ. Response on ‘RE: cost–effectiveness of pertussis booster vaccination in The Netherlands’. Vaccine31(16), 2024 (2013).
   PubMed Web of Science ®Google Scholar
• Rozenbaum MH . Dynamic models for health economic assessments of pertussis vaccines: what goes around comes around. Expert Rev. Vaccines11(12), 1415–1428(2012).
   PubMed Web of Science ®Google Scholar
• Westra TA , de Vries R, Tamminga JJ, Sauboin CJ, Postma MJ. Cost–effectiveness analysis of various pertussis vaccination strategies primarily aimed at protecting infants in The Netherlands. Clin. Ther.32(8), 1479–1495(2010).
   PubMed Web of Science ®Google Scholar
• Rozenbaum MH , SandersEA, van Hoek AJ et al. Cost–effectiveness of pneumococcal vaccination among Dutch infants: economic analysis of the seven valent pneumococcal conjugated vaccine and forecast for the 10 valent and 13 valent vaccines. BMJ340, c2509 (2010).
   PubMed Web of Science ®Google Scholar
• Karlsson G , JohannesonM. The decision rules of cost–effectiveness analysis. Pharmacoeconomics2, 113–120(1996).
   Google Scholar
• Miller E , AndrewsNJ, WaightPA, SlackMP, GeorgeRC. Herd immunity and serotype replacement 4 years after seven-valent pneumococcal conjugate vaccination in England and Wales: an observational cohort study. Lancet Infect. Dis.11(10), 760–768(2011).
   PubMed Web of Science ®Google Scholar
• van Deursen AM , van Mens SP, Sanders EA et al. Invasive pneumococcal disease and 7-valent pneumococcal conjugate vaccine, The Netherlands. Emerg. Infect. Dis.18(11), 1729–1737(2012).
   PubMed Web of Science ®Google Scholar
• Rozenbaum MH , HoekAJ, HakE, PostmaMJ. Huge impact of assumptions on indirect effects on the cost–effectiveness of routine infant vaccination with 7-valent conjugate vaccine (Prevnar). Vaccine28(12), 2367–2369(2010).
   PubMed Web of Science ®Google Scholar
• Rozenbaum MH , HakE, van der Werf TS, Postma MJ. Results of a cohort model analysis of the cost–effectiveness of routine immunization with 13-valent pneumococcal conjugate vaccine of those aged > or =65 years in The Netherlands. Clin. Ther.32(8), 1517–1532(2010).
   PubMed Web of Science ®Google Scholar
• Gravelle D , SmithH. Discounting for health effects in cost-benefit and cost–effectiveness analysis. Health Econ.10, 587–599(2001).
   PubMed Web of Science ®Google Scholar
• Brouwer WBF , NiessenLW, PostmaMJ, RuttenFFH. Need for differential discounting of costs and health effects in cost–effectiveness analysis. BMJ331, 446–449(2005).
   PubMed Web of Science ®Google Scholar
• Keeler EB , CretinS. Discounting of life-saving and other nonmonetary effects. Man. Sci.29, 300–306(1983).
   Web of Science ®Google Scholar
• Cost–effectiveness in Health and Medicine. Gold MR, Siegel JE, Russel LB, Weinstein MC (Eds). Oxford University Press, NY, USA (1996).
   Google Scholar

Websites

• Guidelines for cost–effectiveness analysis. www.ispor.nl
   Google Scholar
• College voor Zorgverzekeringen. www.cvz.nl
   Google Scholar
• Belgium Health and Care Knowledge Centre. www.kce.fgov.be
   Google Scholar
• Vlaams Agentschap Zorg en Gezondheid Vaccinaties. www.zorg-en-gezondheid.be/vaccinaties
   Google Scholar
• Pneumococcal infection. www.hpa.org.uk/Topics/InfectiousDiseases/InfectionsAZ/Pneumococcal
   Google Scholar